Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,031 public trials 2,028 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Active, Not Recruiting

Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP

NCT05798156

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Uniklinik Innsbruck Innsbruck, Austria
  • Kepler Universitätsklinikum Linz, Austria
  • Ordensklinikum Linz - Barmherzige Schwestern Linz, Austria
  • Ordensklinikum Linz - Elisabethinen Linz, Austria
View all 28 locations
View Trial Details
Active, Not Recruiting

SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies

NCT04684108

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +20 more
Locations
  • The First Affiliated Hospital of Bengbu Medical College Bengbu, Anhui, China
  • Affiliated Beijing Chaoyang Hospital of Capital Medical University Beijing, Beijing Municipality, China
  • Beijing Jishuitan Hostipal Beijing, Beijing Municipality, China
  • Shenzhen Second People's Hospital Shenzhen, Guangzhou, China
View all 14 locations
View Trial Details
Active, Not Recruiting

Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy

NCT03993912

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Chru Jean Minjoz Besançon, France
  • Ch Blois Simone Veil Blois, France
  • Ch Fleyriat Bourg-en-Bresse, France
  • Chru Brest Site Hopital Morvan Brest, France
View all 23 locations
View Trial Details
Active, Not Recruiting

Study of Acalabrutinib and Tafasitamab in MZL Patients

NCT04646395

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • University of Wien Vienna, Austria
  • ASST Spedali Civili di Brescia Brescia, Italy
  • Fondazione IRCCS - Istituto Nazionale dei Tumori Milan, Italy
  • Fondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico Milan, Italy
View Trial Details
Active, Not Recruiting

9-ING-41 in Patients With Advanced Cancers

NCT03678883

Conditions
Acute T Cell Leukemia Lymphoma, Bone Cancer, Bone Diseases, +90 more
Locations
  • Mayo Clinic Phoenix, Arizona, United States
  • Arizona Oncology Associates Tucson, Arizona, United States
  • The University of Arizona Cancer Center Tucson, Arizona, United States
  • University of California Irvine Health Orange, California, United States
View all 66 locations
View Trial Details

Related conditions